Loading...
Header Logo
Institute for Clinical and Translational Research

Profiles



Video Tutorials
Keywords
Last Name
Institution

ELIAS JOSEPH JABBOUR

TitleAssociate Professor
InstitutionMD Anderson
DepartmentLeukemia
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Aug 07. PMID: 31400961.
      View in: PubMed
    2. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Jul 16. PMID: 31310323.
      View in: PubMed
    3. Jabbour E. Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults. Oncology (Williston Park). 2019 Jul 16; 33(7). PMID: 31365753.
      View in: PubMed
    4. Sasaki K, Kantarjian HM, Jabbour EJ. Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? Cancer. 2019 Jul 10. PMID: 31291004.
      View in: PubMed
    5. Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 Aug; 19(8):471-479. PMID: 31307896.
      View in: PubMed
    6. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. 2019 Jun 27; 1-4. PMID: 31246142.
      View in: PubMed
    7. Jabbour EJ, Mendiola MF, Lingohr-Smith M, Lin J, Makenbaeva D. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. J Med Econ. 2019 May 31; 1-6. PMID: 31074658.
      View in: PubMed
    8. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 May 31. PMID: 31150121.
      View in: PubMed
    9. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103. PMID: 31141631.
      View in: PubMed
    10. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019 May 24; 1-9. PMID: 31125272.
      View in: PubMed
    11. Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2019 May 23. PMID: 31123034.
      View in: PubMed
    12. Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 Aug; 186(4):538-548. PMID: 31115909.
      View in: PubMed
    13. Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Ther Adv Hematol. 2019; 10:2040620719849496. PMID: 31205644.
      View in: PubMed
    14. Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019 May 16; 1-16. PMID: 31092071.
      View in: PubMed
    15. Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327. PMID: 31060979.
      View in: PubMed
    16. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 Aug 01; 125(15):2579-2586. PMID: 30985931.
      View in: PubMed
    17. Mesa RA, Su Y, Woolfson A, Prchal JT, Turnbull K, Jabbour E, Scherber R, Shields AL, Krohe M, Ojo F, Pompilus F, Cappelleri JC, Harrison C. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health Qual Life Outcomes. 2019 Apr 11; 17(1):61. PMID: 30975150.
      View in: PubMed
    18. Richard-Carpentier G, Kantarjian H, Jabbour E. Recent Advances in Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2019 Apr; 14(2):106-118. PMID: 30879177.
      View in: PubMed
    19. Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 Jul 15; 125(14):2474-2487. PMID: 30920645.
      View in: PubMed
    20. Li N, Wang SA, Lin P, Jabbour E, Thompson P, Chen Z, Li S, Xu J, You MJ, Bueso-Ramos CE, Medeiros LJ, Yin CC. Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. Am J Hematol. 2019 Mar 27. PMID: 30916805.
      View in: PubMed
    21. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 Mar 26; 3(6):922-933. PMID: 30902805.
      View in: PubMed
    22. Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 Mar 26; 3(6):851-861. PMID: 30885996.
      View in: PubMed
    23. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol. 2019 Jun; 94(6):E158-E160. PMID: 30838674.
      View in: PubMed
    24. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. 2019 Mar 12. PMID: 30861111.
      View in: PubMed
    25. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552. PMID: 30830579.
      View in: PubMed
    26. Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant. 2019 Jul; 25(7):1347-1354. PMID: 30826465.
      View in: PubMed
    27. Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 Mar; 17(3):166-175. PMID: 30969955.
      View in: PubMed
    28. Corbacioglu S, Jabbour EJ, Mohty M. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biol Blood Marrow Transplant. 2019 Jul; 25(7):1271-1280. PMID: 30797942.
      View in: PubMed
    29. Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Curr Treat Options Oncol. 2019 Jan 24; 20(1):4. PMID: 30675645.
      View in: PubMed
    30. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 May 15; 125(10):1665-1673. PMID: 30668890.
      View in: PubMed
    31. Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 Apr; 94(4):408-416. PMID: 30623490.
      View in: PubMed
    32. Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7. PMID: 30651532.
      View in: PubMed
    33. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 Jul; 60(7):1767-1774. PMID: 30632841.
      View in: PubMed
    34. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 Jan 03; 12(1):1. PMID: 30606227.
      View in: PubMed
    35. Burgos S, Montalban-Bravo G, Fuente L, Jabbour EJ, Kanagal-Shamanna R, Soltysiak KA, Garcia-Manero G, Mela-Osorio MJ. Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. Medicine (Baltimore). 2019 Jan; 98(1):e14011. PMID: 30608448.
      View in: PubMed
    36. Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol. 2019 Jan; 27(1):33-39. PMID: 28682832.
      View in: PubMed
    37. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 Mar; 19(3):142-148.e1. PMID: 30635233.
      View in: PubMed
    38. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37. PMID: 30545576.
      View in: PubMed
    39. Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer. 2019 Apr 01; 125(7):1091-1100. PMID: 30521114.
      View in: PubMed
    40. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol. 2019 Feb; 37(1):96-102. PMID: 30153704.
      View in: PubMed
    41. Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627. PMID: 30501869.
      View in: PubMed
    42. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 May 01; 125(9):1470-1481. PMID: 30500073.
      View in: PubMed
    43. Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019 Feb; 94(2):257-265. PMID: 30394566.
      View in: PubMed
    44. Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. 2019 Mar; 72(3):251-257. PMID: 30467242.
      View in: PubMed
    45. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 Jan; 94(1):74-79. PMID: 30328139.
      View in: PubMed
    46. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383. PMID: 30409776.
      View in: PubMed
    47. Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019 Apr; 104(4):749-755. PMID: 30361418.
      View in: PubMed
    48. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 Nov; 7(11):5457-5469. PMID: 30318751.
      View in: PubMed
    49. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 Oct 15; 124(20):4044-4055. PMID: 30307611.
      View in: PubMed
    50. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 Nov 01; 124(21):4192-4201. PMID: 30307606.
      View in: PubMed
    51. Hidalgo-L?pez JE, Kanagal-Shamanna R, Quesada AE, Gong Z, Wang W, Hu S, Medeiros LJ, Bassett RL, d'Orcy E, Yin CC, Cortes J, Jabbour EJ, Kantarjian HM, Bueso-Ramos CE. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer. 2018 Oct 01; 124(19):3849-3855. PMID: 30321462.
      View in: PubMed
    52. Jabbour E, Pui CH, Kantarjian H. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol. 2018 Oct 01; 4(10):1413-1420. PMID: 29931220.
      View in: PubMed
    53. Li J, Xu J, Abruzzo LV, Tang G, Li S, You MJ, Lu G, Jabbour EJ, Deng Q, Bueso-Ramos CE, Medeiros LJ, Yin CC. Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget. 2018 09 28; 9(76):34449. PMID: 30344953.
      View in: PubMed
    54. Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 10; 93(10):1245-1253. PMID: 30051599.
      View in: PubMed
    55. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. PMID: 30319961.
      View in: PubMed
    56. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383. PMID: 30117185.
      View in: PubMed
    57. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85. PMID: 30245189.
      View in: PubMed
    58. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. PMID: 30185431.
      View in: PubMed
    59. Ok CY, Medeiros LJ, Thakral B, Tang G, Jain N, Jabbour E, Pierce SA, Konoplev S. High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol. 2019 01; 32(1):48-58. PMID: 30181564.
      View in: PubMed
    60. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141. PMID: 30028037.
      View in: PubMed
    61. Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2018; 2. PMID: 31080940.
      View in: PubMed
    62. Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D. Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States. Leuk Lymphoma. 2019 Mar; 60(3):668-674. PMID: 30124372.
      View in: PubMed
    63. Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model. J Med Econ. 2018 Oct; 21(10):1036-1040. PMID: 30071761.
      View in: PubMed
    64. Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018 08 14; 2(15):1807-1816. PMID: 30054307.
      View in: PubMed
    65. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421. PMID: 30115541.
      View in: PubMed
    66. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39. PMID: 30071517.
      View in: PubMed
    67. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670. PMID: 29991687.
      View in: PubMed
    68. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 Nov; 103(11):e514-e518. PMID: 29794146.
      View in: PubMed
    69. Kantarjian H, Jabbour E. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:574-578. PMID: 30231308.
      View in: PubMed
    70. Short NJ, Kantarjian H, Pui CH, Goldstone A, Jabbour E. SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 07; 18(7):439-446. PMID: 29853276.
      View in: PubMed
    71. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 Jul 01; 124(13):2740-2747. PMID: 29723397.
      View in: PubMed
    72. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797. PMID: 29702001.
      View in: PubMed
    73. Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. 2018 11; 32(11):2512-2518. PMID: 29749401.
      View in: PubMed
    74. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398. PMID: 29769624.
      View in: PubMed
    75. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 Jul 01; 124(13):2758-2765. PMID: 29660836.
      View in: PubMed
    76. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 Jun 15; 124(12):2534-2540. PMID: 29645075.
      View in: PubMed
    77. Chiaretti S, Jabbour E, Hoelzer D. "Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):301-310. PMID: 29653823.
      View in: PubMed
    78. Short NJ, Kantarjian H, Jabbour E, Ravandi F. Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2018 04; 13(2):91-99. PMID: 29423571.
      View in: PubMed
    79. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146. PMID: 29550383.
      View in: PubMed
    80. Kurt H, Jorgensen JL, Amin HM, Patel KP, Wang SA, Lin P, Kanagal-Shamanna R, Loghavi S, Thakral B, Khogeer HA, Jabbour EJ, Li S, Yin CC, Medeiros LJ, Khoury JD. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454. PMID: 29385279.
      View in: PubMed
    81. Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Cappelleri JC, Marks DI. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018 May 15; 124(10):2151-2160. PMID: 29508899.
      View in: PubMed
    82. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018 03; 93(3):442-459. PMID: 29411417.
      View in: PubMed
    83. Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol. 2018 Mar; 16(3):216-223. PMID: 29742077.
      View in: PubMed
    84. Montalban-Bravo G, Garcia-Manero G, Jabbour E. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Curr Opin Hematol. 2018 03; 25(2):146-153. PMID: 29266015.
      View in: PubMed
    85. Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia. Am J Clin Oncol. 2018 03; 41(3):213-217. PMID: 26580245.
      View in: PubMed
    86. Rausch CR, Paul S, Marx KR, Jabbour E, Pemmaraju N, Ferrajoli A, Kantarjian H. L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):e191-e195. PMID: 29550108.
      View in: PubMed
    87. Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 05 15; 24(10):2304-2311. PMID: 29476021.
      View in: PubMed
    88. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695. PMID: 29464484.
      View in: PubMed
    89. Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM. Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 04; 18(4):257-265. PMID: 29519619.
      View in: PubMed
    90. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234. PMID: 28859185.
      View in: PubMed
    91. Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 Apr 15; 124(8):1722-1732. PMID: 29381191.
      View in: PubMed
    92. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 2018 Jan 30; 9(8):8027-8041. PMID: 29487712.
      View in: PubMed
    93. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma. 2018 09; 59(9):2238-2241. PMID: 29338567.
      View in: PubMed
    94. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248. PMID: 29352703.
      View in: PubMed
    95. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727. PMID: 29515765.
      View in: PubMed
    96. Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374. PMID: 29178361.
      View in: PubMed
    97. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407. PMID: 29218851.
      View in: PubMed
    98. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168. PMID: 29266206.
      View in: PubMed
    99. Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL, Vence LM, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res. 2018 03 01; 24(5):1011-1018. PMID: 29246938.
      View in: PubMed
    100. Li J, Xu J, Abruzzo LV, Tang G, Li S, You MJ, Lu G, Jabbour EJ, Deng Q, Bueso-Ramos CE, Medeiros LJ, Yin CC. Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget. 2018 Feb 16; 9(13):10987-10994. PMID: 29541391.
      View in: PubMed
    101. Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 01 15; 124(2):325-334. PMID: 29211308.
      View in: PubMed
    102. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285. PMID: 29134664.
      View in: PubMed
    103. Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 01; 93(1):84-90. PMID: 29027261.
      View in: PubMed
    104. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99. PMID: 29047158.
      View in: PubMed
    105. El Fakih R, Jabbour E, Ravandi F, Hassanein M, Anjum F, Ahmed S, Kantarjian H. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol. 2018 Feb; 93(2):286-295. PMID: 28971501.
      View in: PubMed
    106. Short NJ, Kantarjian H, Jabbour E. Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer. 2017 12 15; 123(24):4935-4936. PMID: 29053172.
      View in: PubMed
    107. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322. PMID: 28972430.
      View in: PubMed
    108. Saglio G, Jabbour E. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma. 2018 07; 59(7):1523-1538. PMID: 28972424.
      View in: PubMed
    109. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302. PMID: 28850699.
      View in: PubMed
    110. Boddu P, Yin CC, Kanagal-Shamanna R, Tang G, Thakral B, Kadia T, Konopleva M, Jabbour E, Jain N. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. Case Rep Hematol. 2017; 2017:2413587. PMID: 29075538.
      View in: PubMed
    111. Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, Jabbour E, Bomalaski JS, Chen YP, Hsiao HH, Wang MC, Kuo CY, Chang H, Yeh SP, Cortes J, Chen LT, Chen TY. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Sci Rep. 2017 09 12; 7(1):11253. PMID: 28900115.
      View in: PubMed
    112. Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. 2017 12; 102(12):e514-e517. PMID: 28860345.
      View in: PubMed
    113. Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):1012-1015. PMID: 28838278.
      View in: PubMed
    114. Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859. PMID: 28841236.
      View in: PubMed
    115. Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 10; 18(10):1317-1326. PMID: 28844816.
      View in: PubMed
    116. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017 11 09; 130(19):2084-2091. PMID: 28835440.
      View in: PubMed
    117. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901. PMID: 28927784.
      View in: PubMed
    118. Paul S, Rausch CR, Kantarjian H, Jabbour EJ. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242. PMID: 28776425.
      View in: PubMed
    119. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522. PMID: 28774880.
      View in: PubMed
    120. Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597. PMID: 28646517.
      View in: PubMed
    121. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402. PMID: 28743165.
      View in: PubMed
    122. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717. PMID: 28729302.
      View in: PubMed
    123. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928. PMID: 28556489.
      View in: PubMed
    124. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774.
      View in: PubMed
    125. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820. PMID: 28718728.
      View in: PubMed
    126. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439. PMID: 28708931.
      View in: PubMed
    127. Jabbour EJ, Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva D. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. J Med Econ. 2017 Sep; 20(9):1007-1012. PMID: 28681664.
      View in: PubMed
    128. Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug; 4(8):e387-e398. PMID: 28687420.
      View in: PubMed
    129. Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131. PMID: 28674026.
      View in: PubMed
    130. Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 2017 10; 102(10):1661-1670. PMID: 28659335.
      View in: PubMed
    131. Short NJ, Kantarjian H, Jabbour E, Ravandi F. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2017 09; 30(3):193-200. PMID: 29050692.
      View in: PubMed
    132. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444. PMID: 28616864.
      View in: PubMed
    133. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724. PMID: 28608976.
      View in: PubMed
    134. Kantarjian H, Jabbour E, Topp MS. Blinatumomab for Acute Lymphoblastic Leukemia. N Engl J Med. 2017 06 08; 376(23):e49. PMID: 28591537.
      View in: PubMed
    135. Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol. 2017 Jul; 92(7):660-667. PMID: 28370201.
      View in: PubMed
    136. Short NJ, Jabbour E. Yes, treatment for CML should continue indefinitely. Clin Adv Hematol Oncol. 2017 Jun; 15(6):489-492. PMID: 28749909.
      View in: PubMed
    137. Kanagal-Shamanna R, Hidalgo Lopez JE, Milton DR, Kim HR, Zhao C, Zuo Z, Janania Martinez M, Stingo F, Lee J, Luthra R, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. Am J Hematol. 2017 08; 92(8):E168-E171. PMID: 28456995.
      View in: PubMed
    138. Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606. PMID: 28370097.
      View in: PubMed
    139. Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL, Khouri IF. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1405-1410. PMID: 28495642.
      View in: PubMed
    140. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117. PMID: 28295472.
      View in: PubMed
    141. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. PMID: 28387922.
      View in: PubMed
    142. Salem A, Loghavi S, Tang G, Huh YO, Jabbour EJ, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury JD. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol. 2017 Jun; 92(6):520-528. PMID: 28253536.
      View in: PubMed
    143. Yilmaz M, Kantarjian H, Jabbour E. Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol. 2017 Apr; 15(4):266-274. PMID: 28591103.
      View in: PubMed
    144. Rytting ME, Jabbour EJ, O'Brien SM, Kantarjian HM. Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403. PMID: 28328172.
      View in: PubMed
    145. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587. PMID: 28246192.
      View in: PubMed
    146. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337. PMID: 28052408.
      View in: PubMed
    147. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358. PMID: 28076892.
      View in: PubMed
    148. Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6. PMID: 28278723.
      View in: PubMed
    149. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243. PMID: 28006851.
      View in: PubMed
    150. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285. PMID: 28052371.
      View in: PubMed
    151. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. Am J Hematol. 2017 Feb; 92(2):155-160. PMID: 27874212.
      View in: PubMed
    152. Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017 May 15; 123(6):994-1002. PMID: 28094841.
      View in: PubMed
    153. Short NJ, Jabbour E. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. Curr Oncol Rep. 2017 Jan; 19(1):6. PMID: 28205134.
      View in: PubMed
    154. Jabbour E, Kantarjian H. Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Adv. 2016 Dec 27; 1(3):260-264. PMID: 29296940.
      View in: PubMed
    155. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283. PMID: 28003274.
      View in: PubMed
    156. Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017 Feb; 110:20-34. PMID: 28109402.
      View in: PubMed
    157. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11. PMID: 27673440.
      View in: PubMed
    158. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017 02 02; 129(5):572-581. PMID: 27919910.
      View in: PubMed
    159. Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol. 2017 Jan; 92(1):E3-E4. PMID: 27727470.
      View in: PubMed
    160. Paul S, Kantarjian H, Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016 Nov; 91(11):1645-1666. PMID: 27814839.
      View in: PubMed
    161. Short NJ, Jabbour E. Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patients. Clin Adv Hematol Oncol. 2016 Nov; 14(11):892-894. PMID: 27930640.
      View in: PubMed
    162. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616. PMID: 27763690.
      View in: PubMed
    163. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637. PMID: 27741352.
      View in: PubMed
    164. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467. PMID: 27696391.
      View in: PubMed
    165. Huang L, Wang SA, Konoplev S, Bueso-Ramos CE, Thakral B, Miranda RN, Jabbour E, Medeiros LJ, Kanagal-Shamanna R. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. Medicine (Baltimore). 2016 Oct; 95(41):e4934. PMID: 27741105.
      View in: PubMed
    166. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435. PMID: 27657543.
      View in: PubMed
    167. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302. PMID: 27602508.
      View in: PubMed
    168. Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol. 2016 12; 91(12):1221-1226. PMID: 27474808.
      View in: PubMed
    169. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820. PMID: 27508525.
      View in: PubMed
    170. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016 11; 16(11):616-624. PMID: 27601000.
      View in: PubMed
    171. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343. PMID: 27509035.
      View in: PubMed
    172. Hoehn D, Cortes JE, Medeiros LJ, Jabbour EJ, Hidalgo JE, Kanagal-Shamanna R, Bueso-Ramos CE. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S86-92. PMID: 27521332.
      View in: PubMed
    173. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656. PMID: 27479888.
      View in: PubMed
    174. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491. PMID: 27463065.
      View in: PubMed
    175. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23. PMID: 27178680.
      View in: PubMed
    176. Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol. 2016 08; 91(8):800-5. PMID: 27169385.
      View in: PubMed
    177. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7. PMID: 27235138.
      View in: PubMed
    178. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7. PMID: 27175025.
      View in: PubMed
    179. Huang L, Garcia-Manero G, Jabbour E, Goswami M, Routbort MJ, Medeiros LJ, Jorgensen JL, Wang SA. Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. J Clin Pathol. 2016 Apr 15. PMID: 27083210.
      View in: PubMed
    180. Jabbour E, Kantarjian H. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Lancet. 2016 Jun 11; 387(10036):2360-1. PMID: 27080497.
      View in: PubMed
    181. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87. PMID: 26871476.
      View in: PubMed
    182. Dahl J, Marx K, Jabbour E. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol. 2016; 9(4):329-34. PMID: 26783163.
      View in: PubMed
    183. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 06 15; 122(12):1871-9. PMID: 26990290.
      View in: PubMed
    184. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 06; 101(6):e224-7. PMID: 26992944.
      View in: PubMed
    185. Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508. PMID: 26968357.
      View in: PubMed
    186. Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Wang SA. Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leuk Lymphoma. 2016; 57(4):812-9. PMID: 26293512.
      View in: PubMed
    187. Wang ES, Jabbour EJ, Douer D. Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium. Clin Adv Hematol Oncol. 2016 Mar; 14(3 Suppl 4):1-23. PMID: 27007406.
      View in: PubMed
    188. Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol. 2016 Jun; 91(4):E274-6. PMID: 26798971.
      View in: PubMed
    189. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. PMID: 26800008.
      View in: PubMed
    190. Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen IM, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui CH, Gastier-Foster J, Gu Z, Reshmi S, Loh ML, Racevskis J, Tallman MS, Wiernik PH, Litzow MR, Willman CL, McPherson JD, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell. 2016 Feb 08; 29(2):186-200. PMID: 26859458.
      View in: PubMed
    191. Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. 2016 Apr; 173(1):114-26. PMID: 26846160.
      View in: PubMed
    192. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016 Feb; 91(2):252-65. PMID: 26799612.
      View in: PubMed
    193. DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes J, Kantarjian H. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 2016 Feb; 91(2):227-32. PMID: 26799610.
      View in: PubMed
    194. George B, Kantarjian H, Jabbour E, Jain N. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 2016 Feb; 8(2):135-43. PMID: 26780449.
      View in: PubMed
    195. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9. PMID: 26747249.
      View in: PubMed
    196. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75. PMID: 26729897.
      View in: PubMed
    197. Chamseddine AN, Jabbour E, Kantarjian HM, Bohannan ZS, Garcia-Manero G. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep. 2016 Jan; 18(1):4. PMID: 26700507.
      View in: PubMed
    198. Jabbour E. Chronic myeloid leukemia: First-line drug of choice. Am J Hematol. 2016 Jan; 91(1):59-66. PMID: 26769227.
      View in: PubMed
    199. Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb; 41:43-7. PMID: 26777537.
      View in: PubMed
    200. Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45. PMID: 26775883.
      View in: PubMed
    201. Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):152-62. PMID: 26796981.
      View in: PubMed
    202. Jabbour EJ. Use of PCR testing in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2015 Dec; 13(12):808-10. PMID: 27058845.
      View in: PubMed
    203. McGarry LJ, Chen YJ, Divino V, Pokras S, Taylor CR, Munakata J, Nieset CC, Huang H, Jabbour E, Malone DC. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Curr Med Res Opin. 2016; 32(2):289-99. PMID: 26566171.
      View in: PubMed
    204. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2. PMID: 26752456.
      View in: PubMed
    205. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205.
      View in: PubMed
    206. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48. PMID: 26479889.
      View in: PubMed
    207. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015 Dec; 39(12):1367-74. PMID: 26547258.
      View in: PubMed
    208. Vitale C, Lu X, Abderrahman B, Takahashi K, Ravandi F, Jabbour E. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. Am J Hematol. 2015 Nov; 90(11):E211-2. PMID: 26257212.
      View in: PubMed
    209. Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015 Oct; 6(5):253-61. PMID: 26425338.
      View in: PubMed
    210. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555. PMID: 26432046.
      View in: PubMed
    211. Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines. Clin Lymphoma Myeloma Leuk. 2015 Dec; 15(12):797-802. PMID: 26603185.
      View in: PubMed
    212. Yilmaz M, Jabbour E. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia. Semin Oncol. 2015 Dec; 42(6):876-86. PMID: 26615132.
      View in: PubMed
    213. Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica. 2015 Dec; 100(12):e494-5. PMID: 26341741.
      View in: PubMed
    214. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015 Sep; 2(9):e376-83. PMID: 26436130.
      View in: PubMed
    215. Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. J Clin Oncol. 2015 Nov 20; 33(33):3953-60. PMID: 26324368.
      View in: PubMed
    216. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885.
      View in: PubMed
    217. Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110. PMID: 26296954.
      View in: PubMed
    218. Bryan JC, Jabbour EJ. Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. Drugs Aging. 2015 Aug; 32(8):623-37. PMID: 26286093.
      View in: PubMed
    219. Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol. 2015 Aug; 90(8):752-3. PMID: 25850565.
      View in: PubMed
    220. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul 31; 5:e333. PMID: 26230957.
      View in: PubMed
    221. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036. PMID: 26234174.
      View in: PubMed
    222. Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904. PMID: 26217876.
      View in: PubMed
    223. Waked N, Jabbour E, Matar D, Antoun J, Abdelmassih Y. [Establishment of a normative database for retinal nerve fiber layer thickness in a Lebanese population]. J Fr Ophtalmol. 2015 Oct; 38(8):e179-86. PMID: 26213302.
      View in: PubMed
    224. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7. PMID: 26124496.
      View in: PubMed
    225. Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Cain Z, Okoro T, Bolinder B, Patt D, Jabbour EJ. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting. Clin Lymphoma Myeloma Leuk. 2015 Oct; 15(10):599-605. PMID: 26208445.
      View in: PubMed
    226. Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug; 100(8):1058-63. PMID: 26088933.
      View in: PubMed
    227. Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6. PMID: 26183878.
      View in: PubMed
    228. Mattiuzzi G, Yilmaz M, Kantarjian H, Borthakur G, Konopleva M, Jabbour E, Brown Y, Pierce S, Cortes J. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. J Infect Chemother. 2015 Sep; 21(9):663-7. PMID: 26141814.
      View in: PubMed
    229. Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62. PMID: 26141213.
      View in: PubMed
    230. Jabbour EJ. An ALL patient with a t(4;11) translocation. Clin Adv Hematol Oncol. 2015 Jun; 13(6 Suppl 7):12-3. PMID: 26431323.
      View in: PubMed
    231. Wang ES, Jabbour EJ, Douer D. Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium. Clin Adv Hematol Oncol. 2015 Jun; 13(6 Suppl 7):1-23. PMID: 26431322.
      View in: PubMed
    232. Yilmaz M, Abaza Y, Jabbour E. Selecting the best frontline treatment in chronic myeloid leukemia. Curr Hematol Malig Rep. 2015 Jun; 10(2):145-57. PMID: 25921387.
      View in: PubMed
    233. Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015 Jun 25; 125(26):4010-6. PMID: 25999456.
      View in: PubMed
    234. Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93. PMID: 26688093.
      View in: PubMed
    235. Shen Q, Ouyang J, Tang G, Jabbour EJ, Garcia-Manero G, Routbort M, Konoplev S, Bueso-Ramos C, Medeiros LJ, Jorgensen JL, Wang SA. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol. 2015 Aug; 95(2):168-76. PMID: 25354960.
      View in: PubMed
    236. Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015 Aug 01; 121(15):2517-28. PMID: 25891003.
      View in: PubMed
    237. Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015 Jul; 100(7):898-904. PMID: 25887498.
      View in: PubMed
    238. Mace ML, Dahl J, Jabbour EJ. Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia? Expert Opin Pharmacother. 2015 May; 16(7):999-1007. PMID: 25840461.
      View in: PubMed
    239. Ohanian M, Kantarjian H, Guy D, Thomas D, Jabbour E, O'Brien S. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther. 2015 Apr; 15(4):601-11. PMID: 25775418.
      View in: PubMed
    240. Dahl J, Mace M, Kantarjian H, Jabbour E. Blinatumomab for the treatment of adult acute lymphoblastic leukemia. Drugs Today (Barc). 2015 Apr; 51(4):231-41. PMID: 26020065.
      View in: PubMed
    241. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1405-1412. PMID: 25840338.
      View in: PubMed
    242. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15; 121(14):2375-82. PMID: 25809968.
      View in: PubMed
    243. Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):323-34. PMID: 25971713.
      View in: PubMed
    244. Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015 Mar; 2(3):e118-28. PMID: 26687797.
      View in: PubMed
    245. Cabrero M, Jabbour E, Ravandi F, Bohannan Z, Pierce S, Kantarjian HM, Garcia-Manero G. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015 May; 39(5):520-4. PMID: 25828745.
      View in: PubMed
    246. Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73. PMID: 25764322.
      View in: PubMed
    247. Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14. PMID: 25724525.
      View in: PubMed
    248. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3. PMID: 25716073.
      View in: PubMed
    249. Jabbour E, Garcia-Manero G. Deacetylase inhibitors for the treatment of myelodysplastic syndromes. Leuk Lymphoma. 2015 May; 56(5):1205-12. PMID: 25058371.
      View in: PubMed
    250. Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015 May; 100(5):653-61. PMID: 25682595.
      View in: PubMed
    251. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34. PMID: 25682597.
      View in: PubMed
    252. Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F. Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leuk Lymphoma. 2015 Feb; 56(2):395-400. PMID: 24794806.
      View in: PubMed
    253. Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6. PMID: 25407953.
      View in: PubMed
    254. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20. PMID: 26687423.
      View in: PubMed
    255. Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015 Mar 01; 21(5):985-94. PMID: 25480830.
      View in: PubMed
    256. Roboz GJ, Jabbour EJ, Faderl S, Douer D. Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium. Clin Adv Hematol Oncol. 2014 Dec; 12(12 Suppl 20):8-18, 1. PMID: 25768269.
      View in: PubMed
    257. Debiane L, Hachem RY, Al Wohoush I, Shomali W, Bahu RR, Jiang Y, Chaftari AM, Jabbour J, Al Shuaibi M, Hanania A, Pravinkumar SE, Schuetz P, Raad I. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. Crit Care Med. 2014 Dec; 42(12):2500-7. PMID: 25083975.
      View in: PubMed
    258. Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7. PMID: 25413673.
      View in: PubMed
    259. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4. PMID: 25368968.
      View in: PubMed
    260. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15; 121(6):876-82. PMID: 25410759.
      View in: PubMed
    261. Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61. PMID: 25336333.
      View in: PubMed
    262. Kantarjian H, O'Brien S, Jabbour E, Barnes G, Pathak A, Cortes J. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):13-21. PMID: 25458084.
      View in: PubMed
    263. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6. PMID: 25441108.
      View in: PubMed
    264. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014 Oct 02; 124(14):2306-12. PMID: 25145344.
      View in: PubMed
    265. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442. PMID: 25132497.
      View in: PubMed
    266. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma. 2015 Apr; 56(4):1012-9. PMID: 25048874.
      View in: PubMed
    267. Poon ML, Fox PS, Samuels BI, O'Brien S, Jabbour E, Hsu Y, Gulbis A, Korbling M, Champlin R, Abruzzo LV, Bassett RL, Khouri IF. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma. 2015 Mar; 56(3):711-5. PMID: 24913509.
      View in: PubMed
    268. Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65. PMID: 25066676.
      View in: PubMed
    269. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8. PMID: 24990142.
      View in: PubMed
    270. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. PMID: 25042398.
      View in: PubMed
    271. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4. PMID: 24844364.
      View in: PubMed
    272. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4. PMID: 25107338.
      View in: PubMed
    273. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9. PMID: 25047979.
      View in: PubMed
    274. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1618-25. PMID: 24953017.
      View in: PubMed
    275. Mathisen MS, Kantarjian HM, Cortes J, Jabbour EJ. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014 Sep; 28(5):179-87. PMID: 24984571.
      View in: PubMed
    276. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10. PMID: 24875590.
      View in: PubMed
    277. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014 May; 89(5):547-56. PMID: 24729196.
      View in: PubMed
    278. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol. 2014 Apr; 5(2):29-34. PMID: 24688752.
      View in: PubMed
    279. Jabbour E. Treating myelodysplastic syndrome when hypomethylating agents stop working. Clin Adv Hematol Oncol. 2014 Apr; 12(4):257-9. PMID: 25003355.
      View in: PubMed
    280. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8. PMID: 24375514.
      View in: PubMed
    281. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7. PMID: 24779033.
      View in: PubMed
    282. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795.
      View in: PubMed
    283. Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014 May; 89(5):509-16. PMID: 24458781.
      View in: PubMed
    284. Kyvernitakis A, Jabbour E, Torres HA. Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor. Clin Infect Dis. 2014 May; 58(9):1342-4. PMID: 24501385.
      View in: PubMed
    285. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9. PMID: 24138309.
      View in: PubMed
    286. Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):395-400.e1. PMID: 24637132.
      View in: PubMed
    287. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5. PMID: 24487412.
      View in: PubMed
    288. Bryan J, Kantarjian H, Prescott H, Jabbour E. Clofarabine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2014 Feb; 23(2):255-63. PMID: 24410313.
      View in: PubMed
    289. Quintás-Cardama A, Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8. PMID: 24594142.
      View in: PubMed
    290. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61. PMID: 24492324.
      View in: PubMed
    291. Jabbour E, Ottmann OG, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica. 2014 Jan; 99(1):7-18. PMID: 24425689.
      View in: PubMed
    292. Mathisen MS, Kantarjian HM, Jabbour EJ. Emerging drugs for acute lymphocytic leukemia. Expert Opin Emerg Drugs. 2014 Mar; 19(1):37-50. PMID: 24354521.
      View in: PubMed
    293. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1. PMID: 24332214.
      View in: PubMed
    294. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23; 123(4):494-500. PMID: 24311723.
      View in: PubMed
    295. Jabbour EJ, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013 Dec; 13(12):1433-52. PMID: 24236822.
      View in: PubMed
    296. Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7. PMID: 24447728.
      View in: PubMed
    297. Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. 2014 Jul; 55(7):1451-62. PMID: 24050507.
      View in: PubMed
    298. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5. PMID: 24157581.
      View in: PubMed
    299. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 01; 120(3):373-80. PMID: 24151050.
      View in: PubMed
    300. Jabbour E, Cortes J, Ravandi F, O'Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013 Oct; 50(4):271-83. PMID: 24246694.
      View in: PubMed
    301. Jabbour E, Lipton JH. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):646-56. PMID: 24095296.
      View in: PubMed
    302. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9. PMID: 24060289.
      View in: PubMed
    303. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9. PMID: 23913852.
      View in: PubMed
    304. Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec; 55(12):2879-86. PMID: 23927391.
      View in: PubMed
    305. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926.
      View in: PubMed
    306. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81. PMID: 23969309.
      View in: PubMed
    307. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94. PMID: 23969308.
      View in: PubMed
    308. Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29. PMID: 23890944.
      View in: PubMed
    309. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4. PMID: 23890523.
      View in: PubMed
    310. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7. PMID: 23760779.
      View in: PubMed
    311. Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov; 98(11):1686-8. PMID: 23812943.
      View in: PubMed
    312. Mathisen MS, Kantarjian H, Thomas D, O'Brien S, Jabbour E. Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leuk Lymphoma. 2013 Dec; 54(12):2592-600. PMID: 23547835.
      View in: PubMed
    313. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6. PMID: 23790798.
      View in: PubMed
    314. Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84. PMID: 23770156.
      View in: PubMed
    315. Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):559-67. PMID: 23763917.
      View in: PubMed
    316. Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40. PMID: 23763915.
      View in: PubMed
    317. Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H. Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):579-83. PMID: 23763918.
      View in: PubMed
    318. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3. PMID: 23774633.
      View in: PubMed
    319. Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53. PMID: 23733767.
      View in: PubMed
    320. Antoun J, Rami HE, Jabbour E, Chelala E. [Sixth, seventh and tenth cranial nerve palsies associated with pseudotumor cerebri in a 13-year-old boy]. J Fr Ophtalmol. 2013 Nov; 36(9):e173-6. PMID: 23731791.
      View in: PubMed
    321. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36. PMID: 23633004.
      View in: PubMed
    322. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74. PMID: 23620574.
      View in: PubMed
    323. Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013 Jul 15; 119(14):2611-9. PMID: 23605952.
      View in: PubMed
    324. Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013 Apr; 4(2):103-17. PMID: 23610618.
      View in: PubMed
    325. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. PMID: 23512829.
      View in: PubMed
    326. Quintás-Cardama A, Jabbour EJ. Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib. Leuk Res. 2013 May; 37(5):487-95. PMID: 23391518.
      View in: PubMed
    327. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200. PMID: 23345254.
      View in: PubMed
    328. Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):302-6. PMID: 23318257.
      View in: PubMed
    329. Al Shuaibi M, Bahu RR, Chaftari AM, Al Wohoush I, Shomali W, Jiang Y, Debiane L, Raad S, Jabbour J, Al Akhrass F, Hachem RY, Raad I. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis. 2013 Apr; 56(7):943-50. PMID: 23288950.
      View in: PubMed
    330. Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintás-Cardama A. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):139-43. PMID: 23276886.
      View in: PubMed
    331. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8. PMID: 23260600.
      View in: PubMed
    332. Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):342-6. PMID: 23246163.
      View in: PubMed
    333. Jabbour EJ, Bixby D, Akard LP. Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2012 Dec; 10(12 Suppl 22):1-16. PMID: 23271195.
      View in: PubMed
    334. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42. PMID: 23135353.
      View in: PubMed
    335. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13. PMID: 23174881.
      View in: PubMed
    336. Chen L, Guérin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin. 2012 Nov; 28(11):1831-9. PMID: 23127201.
      View in: PubMed
    337. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012 Nov; 87(11):1037-45. PMID: 23090888.
      View in: PubMed
    338. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9. PMID: 23115106.
      View in: PubMed
    339. Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3. PMID: 23086624.
      View in: PubMed
    340. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104. PMID: 23075701.
      View in: PubMed
    341. Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma. 2013 Apr; 54(4):688-98. PMID: 22957815.
      View in: PubMed
    342. Jabbour E, Mathisen MS, O'Brien S. 10 years of progress in chronic myelogenous leukemia. J Natl Compr Canc Netw. 2012 Sep; 10(9):1049-53. PMID: 22956803.
      View in: PubMed
    343. Mathisen MS, Jabbour E, Kantarjian HM. Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies. Oncology (Williston Park). 2012 Sep; 26(9):851-9. PMID: 23061343.
      View in: PubMed
    344. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9. PMID: 22718840.
      View in: PubMed
    345. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31. PMID: 22665218.
      View in: PubMed
    346. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200. PMID: 22578814.
      View in: PubMed
    347. Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):223-9. PMID: 22633166.
      View in: PubMed
    348. Shomali W, Hachem R, Chaftari AM, Jiang Y, Bahu R, Jabbour J, Raad S, Al Shuaibi M, Al Wohoush I, Raad I. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? Cancer. 2012 Dec 01; 118(23):5823-9. PMID: 22605389.
      View in: PubMed
    349. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10. PMID: 22585696.
      View in: PubMed
    350. Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother. 2012 May; 13(7):927-38. PMID: 22519766.
      View in: PubMed
    351. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616.
      View in: PubMed
    352. Jabbour EJ, Kantarjian H, Eliasson L, Cornelison AM, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012 Jul; 87(7):687-91. PMID: 22473898.
      View in: PubMed
    353. Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012 May 10; 119(19):4524-6. PMID: 22431574.
      View in: PubMed
    354. Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother. 2012 Apr; 13(6):815-28. PMID: 22429140.
      View in: PubMed
    355. Jabbour EJ, Quintás-Cardama A. Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response. Leuk Lymphoma. 2012 Aug; 53(8):1452-60. PMID: 22273251.
      View in: PubMed
    356. Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012 Jun 15; 118(12):3116-22. PMID: 22370904.
      View in: PubMed
    357. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20. PMID: 22360602.
      View in: PubMed
    358. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11. PMID: 22357140.
      View in: PubMed
    359. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7. PMID: 22282348.
      View in: PubMed
    360. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35. PMID: 22271898.
      View in: PubMed
    361. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer. 2012 Sep 15; 118(18):4462-70. PMID: 22252728.
      View in: PubMed
    362. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol. 2012 Mar; 87(3):317-8. PMID: 22228403.
      View in: PubMed
    363. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7. PMID: 22228624.
      View in: PubMed
    364. Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol. 2012 Jan-Feb; 10(1):14-24. PMID: 22244674.
      View in: PubMed
    365. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9. PMID: 22072492.
      View in: PubMed
    366. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer. 2012 Mar 01; 118(5):1181-91. PMID: 22038681.
      View in: PubMed
    367. Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011 Oct; 25(5):981-95, v. PMID: 22054730.
      View in: PubMed
    368. Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011 Nov 10; 29(32):4260-5. PMID: 21990394.
      View in: PubMed
    369. Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011 Dec 01; 118(23):6030-6. PMID: 21976672.
      View in: PubMed
    370. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol. 2011 Oct; 38(5):682-92. PMID: 21943675.
      View in: PubMed
    371. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3. PMID: 21868570.
      View in: PubMed
    372. Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011 Oct 20; 118(16):4353-8. PMID: 21846902.
      View in: PubMed
    373. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011 Oct; 11(5):421-6. PMID: 21831744.
      View in: PubMed
    374. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011 Oct 27; 118(17):4541-6; quiz 4759. PMID: 21803854.
      View in: PubMed
    375. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8. PMID: 21751197.
      View in: PubMed
    376. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10; 29(23):3173-8. PMID: 21747082.
      View in: PubMed
    377. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2011 Jun; 4(3):253-60. PMID: 21668392.
      View in: PubMed
    378. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011 Jul 28; 118(4):899-902. PMID: 21622644.
      View in: PubMed
    379. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20; 29(18):2521-7. PMID: 21576646.
      View in: PubMed
    380. Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol. 2011 May; 7(5):661-72. PMID: 21500965.
      View in: PubMed
    381. Cornelison AM, Welch MA, Koller C, Jabbour E. Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S111-3. PMID: 22035739.
      View in: PubMed
    382. Champlin R, Jabbour E, Kebriaei P, Anderlini P, Andersson B, de Lima M. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S96-100. PMID: 22035758.
      View in: PubMed
    383. Cornelison AM, Kantarjian H, Cortes J, Jabbour E. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S101-10. PMID: 22035738.
      View in: PubMed
    384. Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. 2011 Nov 15; 117(22):5085-93. PMID: 21523765.
      View in: PubMed
    385. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9. PMID: 21509801.
      View in: PubMed
    386. Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):237-41. PMID: 21575929.
      View in: PubMed
    387. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May 26; 117(21):5600-6. PMID: 21467546.
      View in: PubMed
    388. Mathisen MS, Kantarjian HM, Cortes J, Jabbour E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9. PMID: 21357713.
      View in: PubMed
    389. Quintás-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21. PMID: 21357704.
      View in: PubMed
    390. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1674-83. PMID: 21307148.
      View in: PubMed
    391. Fullmer A, Kantarjian H, Cortes J, Jabbour E. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2011 Feb; 52 Suppl 1:81-91. PMID: 21299461.
      View in: PubMed
    392. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31; 117(13):3641-7. PMID: 21156844.
      View in: PubMed
    393. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011 May 01; 117(9):1800-11. PMID: 21509757.
      View in: PubMed
    394. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother. 2010 Dec; 11(18):3065-72. PMID: 21073351.
      View in: PubMed
    395. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011 Feb 10; 117(6):1822-7. PMID: 21030554.
      View in: PubMed
    396. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44. PMID: 20960519.
      View in: PubMed
    397. Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer. 2011 Mar 01; 117(5):897-906. PMID: 20945321.
      View in: PubMed
    398. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer. 2010 Oct 01; 116(19):4580-9. PMID: 20572037.
      View in: PubMed
    399. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol. 2010 Oct; 47(4):344-53. PMID: 20875551.
      View in: PubMed
    400. Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2011 Feb; 25(2):201-10. PMID: 20861918.
      View in: PubMed
    401. Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer. 2011 Jan 15; 117(2):327-35. PMID: 20845478.
      View in: PubMed
    402. Yin CC, Cortes J, Galbincea J, Reddy N, Breeden M, Jabbour E, Luthra R, Jones D. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010 Sep; 101(9):2005-10. PMID: 20557306.
      View in: PubMed
    403. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15; 116(24):5568-74. PMID: 20737576.
      View in: PubMed
    404. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15; 116(16):3830-4. PMID: 20564137.
      View in: PubMed
    405. Parikh SA, Kadia T, Jabbour E. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. Clin Lymphoma Myeloma Leuk. 2010 Aug; 10(4):301-2. PMID: 20709669.
      View in: PubMed
    406. Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. Drugs. 2010 Jul 30; 70(11):1381-94. PMID: 20614946.
      View in: PubMed
    407. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9. PMID: 20668231.
      View in: PubMed
    408. Bryan J, Jabbour E, Prescott H, Kantarjian H. Thrombocytopenia in patients with myelodysplastic syndromes. Semin Hematol. 2010 Jul; 47(3):274-80. PMID: 20620439.
      View in: PubMed
    409. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood. 2010 Jul 01; 115(26):5428-9. PMID: 20595523.
      View in: PubMed
    410. Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid. 2010 Jun 15; 4:207-13. PMID: 20694077.
      View in: PubMed
    411. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):205-10. PMID: 20511166.
      View in: PubMed
    412. Jabbour E, Fullmer A, Cortés JE, Kantarjian H. Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10 Suppl 1:S6-13. PMID: 20529808.
      View in: PubMed
    413. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer. 2010 May 15; 116(10):2290-300. PMID: 20209620.
      View in: PubMed
    414. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs. 2010 Mar; 15(1):1-11. PMID: 20055690.
      View in: PubMed
    415. Fullmer A, Jabbour E. Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen? Am J Hematol. 2010 Mar; 85(3):158-9. PMID: 20131307.
      View in: PubMed
    416. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol. 2010 Feb; 3(1):15-22. PMID: 21082931.
      View in: PubMed
    417. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8. PMID: 20054352.
      View in: PubMed
    418. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20; 28(3):398-404. PMID: 20008620.
      View in: PubMed
    419. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20; 28(3):392-7. PMID: 20008621.
      View in: PubMed
    420. Jabbour E. Imatinib: high dose versus standard dose. Clin Adv Hematol Oncol. 2009 Dec; 7(12):812-4. PMID: 20332752.
      View in: PubMed
    421. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010 Jan; 24(1):6-12. PMID: 19798095.
      View in: PubMed
    422. Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009 Sep; 22(3):395-407. PMID: 19959090.
      View in: PubMed
    423. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2009 Jul; 4(3):148-56. PMID: 20425428.
      View in: PubMed
    424. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43. PMID: 19567878.
      View in: PubMed
    425. Antaki N, Haffar S, Ali Deeb S, Assaad F, Abou Harb R, Zeibane N, Nasserelddine M, Ibrahim N, Alhaj N, Jabbour E, Aaraj R, Antaki F, Kebbewar K. High prevalence of HBV genotype D in Syria and the clinical characteristics of hepatitis B e antigen-negative chronic hepatitis B. Epidemiol Infect. 2010 Jan; 138(1):40-4. PMID: 19538827.
      View in: PubMed
    426. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009 Aug 01; 27(22):3642-9. PMID: 19506164.
      View in: PubMed
    427. Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol. 2009 Aug 01; 27(22):3659-63. PMID: 19487383.
      View in: PubMed
    428. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905. PMID: 19235255.
      View in: PubMed
    429. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist. 2009 May; 14(5):489-96. PMID: 19365094.
      View in: PubMed
    430. Jabbour E, Soverini S. Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol. 2009 Apr; 46(2 Suppl 3):S22-6. PMID: 19621546.
      View in: PubMed
    431. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63. PMID: 19282457.
      View in: PubMed
    432. Jabbour E, Verstovsek S. Treatment of myelofibrosis in younger patients: to transplant or not? Am J Hematol. 2009 Mar; 84(3):131-2. PMID: 19202548.
      View in: PubMed
    433. Fava C, Kantarjian H, Cortes J, Jabbour E. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther. 2009 Feb 06; 2:233-43. PMID: 19920910.
      View in: PubMed
    434. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 Feb; 84(2):161-9. PMID: 19181650.
      View in: PubMed
    435. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009 Jan; 4(1):3-10. PMID: 19343297.
      View in: PubMed
    436. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5. PMID: 19778850.
      View in: PubMed
    437. Fava C, Cortés JE, Kantarjian H, Jabbour E. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S382-90. PMID: 20007107.
      View in: PubMed
    438. Jabbour E, Cortés JE, Kantarjian H. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9. PMID: 19778852.
      View in: PubMed
    439. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009 Feb 26; 113(9):1892-8. PMID: 19109226.
      View in: PubMed
    440. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009 Mar 05; 113(10):2154-60. PMID: 19060245.
      View in: PubMed
    441. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008 Dec 15; 112(13):4839-42. PMID: 18818391.
      View in: PubMed
    442. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94. PMID: 18615627.
      View in: PubMed
    443. Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant. 2008 Aug; 14(8):859-66. PMID: 18640568.
      View in: PubMed
    444. Jabbour E, El Ahdab S, Cortes J, Kantarjian H. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs. 2008 Jul; 17(7):1127-36. PMID: 18549348.
      View in: PubMed
    445. El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, Bazarbachi A. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res. 2009 Apr; 33(4):565-6. PMID: 18571231.
      View in: PubMed
    446. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun; 112(11):2341-51. PMID: 18398832.
      View in: PubMed
    447. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008 May 15; 112(10):2112-8. PMID: 18348294.
      View in: PubMed
    448. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008 Jul 01; 112(1):53-5. PMID: 18403620.
      View in: PubMed
    449. Jabbour E, Cortés JE, Kantarjian H. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S75-81. PMID: 19254884.
      View in: PubMed
    450. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008 Mar 01; 112(5):1089-95. PMID: 18186499.
      View in: PubMed
    451. Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008 Jan; 8(1):99-110. PMID: 18095887.
      View in: PubMed
    452. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64. PMID: 17989720.
      View in: PubMed
    453. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007 Nov 01; 110(9):2012-8. PMID: 17849460.
      View in: PubMed
    454. Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J. 2007 Nov-Dec; 13(6):357-65. PMID: 18032972.
      View in: PubMed
    455. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302. PMID: 17623836.
      View in: PubMed
    456. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11. PMID: 17785585.
      View in: PubMed
    457. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4. PMID: 17559140.
      View in: PubMed
    458. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15; 110(8):2991-5. PMID: 17625066.
      View in: PubMed
    459. Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2007 Sep; 40(5):431-5. PMID: 17603511.
      View in: PubMed
    460. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs. 2007 Jul; 10(7):468-79. PMID: 17642017.
      View in: PubMed
    461. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007 Jun 15; 109(12):2481-9. PMID: 17497648.
      View in: PubMed
    462. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007 Jun 01; 109(11):2171-81. PMID: 17431887.
      View in: PubMed
    463. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia. 2007 Jul; 21(7):1347-52. PMID: 17495971.
      View in: PubMed
    464. Jabbour E, Cortes J, Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 2007 May; 21(6):653-62; discussion 663-4, 667-8. PMID: 17564324.
      View in: PubMed
    465. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs. 2007 May; 16(5):679-87. PMID: 17461740.
      View in: PubMed
    466. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar; 16(3):381-92. PMID: 17302532.
      View in: PubMed
    467. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 2:S51-7. PMID: 17382013.
      View in: PubMed
    468. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73. PMID: 17133405.
      View in: PubMed
    469. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007 Apr 15; 109(8):3214-8. PMID: 17209054.
      View in: PubMed
    470. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S25-31. PMID: 17292738.
      View in: PubMed
    471. Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol. 2007 Jan; 44(1 Suppl 1):S1-3. PMID: 17292735.
      View in: PubMed
    472. Jabbour E, Cortes J, Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol. 2006 Nov; 18(6):578-83. PMID: 16988578.
      View in: PubMed
    473. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9. PMID: 16955510.
      View in: PubMed
    474. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov. 2006 Sep; 5(9):717-8. PMID: 17001803.
      View in: PubMed
    475. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9. PMID: 16882711.
      View in: PubMed
    476. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73. PMID: 16855631.
      View in: PubMed
    477. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60. PMID: 16803568.
      View in: PubMed
    478. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia. 2006 May; 20(5):814-9. PMID: 16511514.
      View in: PubMed
    479. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3. PMID: 16601247.
      View in: PubMed
    480. Jabbour E, Giles FJ. New agents in myelodysplastic syndromes. Curr Hematol Malig Rep. 2006 Mar; 1(1):25-33. PMID: 20425328.
      View in: PubMed
    481. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 01; 106(5):1090-8. PMID: 16435386.
      View in: PubMed
    482. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc. 2006 Feb; 81(2):247-60. PMID: 16471082.
      View in: PubMed
    483. Yee KW, Jabbour E, Kantarjian HM, Giles FJ. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol. 2005 Dec; 84 Suppl 1:18-24. PMID: 16273408.
      View in: PubMed
    484. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24. PMID: 16278404.
      View in: PubMed
    485. Oprea C, Cainap C, Azoulay R, Assaf E, Jabbour E, Koscielny S, Lapusan S, Vanel D, Bosq J, Ribrag V. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol. 2005 Nov; 131(4):468-71. PMID: 16281936.
      View in: PubMed
    486. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005 Nov; 80(11):1517-27. PMID: 16295033.
      View in: PubMed
    487. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006 Jan 15; 107(2):480-2. PMID: 16195326.
      View in: PubMed
    488. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4. PMID: 16123215.
      View in: PubMed
    489. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6. PMID: 15977212.
      View in: PubMed
    490. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer. 2005 Jun 15; 103(12):2551-7. PMID: 15861412.
      View in: PubMed
    491. Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leuk Lymphoma. 2005 Jun; 46(6):861-7. PMID: 16019530.
      View in: PubMed
    492. Jabbour EJ, Giles FJ. New agents in myelodysplastic syndromes. Curr Hematol Rep. 2005 May; 4(3):191-9. PMID: 15865871.
      View in: PubMed
    493. Jabbour E, Ribrag V. [Acute tumor lysis syndrome: update on therapy]. Rev Med Interne. 2005 Jan; 26(1):27-32. PMID: 15639323.
      View in: PubMed
    494. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95. PMID: 15512806.
      View in: PubMed
    495. Jabbour E, Keating MJ, Champlin RE, Khouri IF. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant? Bone Marrow Transplant. 2004 Aug; 34(4):289-97. PMID: 15220957.
      View in: PubMed
    496. Jabbour E, Chalhoub B, Suzan F, Aloulou S, Cainap C, Toumi N, Fermé C, Carde P, Ribrag V. Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk Lymphoma. 2004 Jul; 45(7):1391-4. PMID: 15359638.
      View in: PubMed
    497. Abboud B, Jabbour E, Chahine G. [Castelman's disease. Report of two cases with review of the literature]. J Med Liban. 2001 Nov-Dec; 49(6):342-6. PMID: 12744638.
      View in: PubMed
    498. Tabchi B, Rassi S, Jabbour E, Haddad A, Ne Hme P, el Rassi B. [Otosclerosis: experience at the Hotel-Dieu in France. 71 surgical cases]. J Med Liban. 2000 May-Jun; 48(3):131-5. PMID: 11268565.
      View in: PubMed
    499. Gammill SL, Tonkin A, Painter M, Jabbour E. CAT scan of the month: lipoma of the right gluteus and thigh. J Tenn Med Assoc. 1982 May; 75(5):339. PMID: 7132336.
      View in: PubMed
    500. Jabbour E, Braund R, Pigott JD. Malignant melanoma: clinical discussion. Am Surg. 1966 Mar; 32(3):193-5. PMID: 4951924.
      View in: PubMed
    501. HARDY JD, JABBOUR E, LOVELACE JR, NEELY WA, WILSON FC. Thermal burns in man. IV. Body weight changes during therapy. Surgery. 1955 Oct; 38(4):685-91. PMID: 13256274.
      View in: PubMed
    502. HARDY JD, LOVELACE JR, JABBOUR E, BRAMLITT EE. Thermal burns in man. VI. Body fluid compartments during early therapy. Am Surg. 1955 Oct; 21(10):969-74. PMID: 13259106.
      View in: PubMed
    503. HARDY JD, NEELY WA, WILSON FC, LOVELACE JR, JABBOUR E. Thermal burns in man. V. Cardiac output during early therapy. Surg Gynecol Obstet. 1955 Jul; 101(1):94-8. PMID: 14396712.
      View in: PubMed
    504. JABBOUR E, HARDY JD. Adrenocortical reserve in debilitated surgical patients. Surg Forum. 1955; 5:587-92. PMID: 13247094.
      View in: PubMed
    505. JABBOUR E. Practical uses of newer therapeutic agents in surgery. Miss Doct. 1954 Oct; 32(5):143-8. PMID: 13203393.
      View in: PubMed
    506. JABBOUR E. ACTH and cortisone therapy: a review. J Tn State Med Assoc. 1954 Apr; 47(4):155-60. PMID: 13152836.
      View in: PubMed
    507. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines. Clinical Lymphoma, Myeloma and Leukemia. 15:797-802e1.
    508. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults. Blood. 127:1863-1869.
    509. Use of PCR testing in chronic myeloid leukemia. Clinical Advances in Hematology and Oncology. 13:808-810.
    510. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clinical Cancer Research. 21:985-994.
    511. Treatment options for tyrosine kinase inhibitor-resistant chronic myeloid leukemia. 79-96.
    512. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 8:135-143.
    513. An all patient with a t(4;11) translocation. Clinical Advances in Hematology and Oncology. 13:12-13.
    514. Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly. Drugs and Aging. 32:623-637.
    515. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    516. Introduction. Seminars in Hematology. 44:1-3.
    517. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal. 5.
    518. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell. 29:186-200.
    519. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology.
    520. Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proceedings. 91:1645-1666.
    521. Decitabine for the treatment of acute myeloid leukemia. Expert Opinion on Orphan Drugs. 1:661-673.
    522. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Current Medical Research and Opinion. 32:289-299.
    523. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 122:238-248.
    524. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. American Journal of Hematology. 91:E274-E276.
    525. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica. 100:e494-e495.
    526. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). American Journal of Hematology. 91:227-232.
    527. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia.
    528. Management of tyrosine kinase inhibitors resistance. 129-156.
    529. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia. The Lancet Haematology. 2:e12-e20.
    530. Deacetylase inhibitors for the treatment of myelodysplastic syndromes. Leukemia and Lymphoma. 56:1205-1212.
    531. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. European Journal of Haematology. 95:168-176.
    532. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 30:649-657.
    533. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia Research. 41:43-47.
    534. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clinical Lymphoma, Myeloma and Leukemia. 16:152-162.
    535. Erratum. Leukemia. 25:385.
    536. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.
    537. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    538. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100:927-934.
    539. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 128:504-507.
    540. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia. 15:556-562.
    541. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma. 56:390-394.
    542. ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia. American Journal of Hematology. 85:277-280.
    543. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 100:898-904.
    544. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 16:S86-S92.
    545. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer.
    546. Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs). Leukemia and Lymphoma. 57:812-819.
    547. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 100:1058-1063.
    548. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    549. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLoS One. 10.
    550. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia and Lymphoma. 55:1451-1462.
    551. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Design, Development and Therapy. 233-243.
    552. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.
    553. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 101:e224-e227.
    554. Treating relapsed/refractory all in younger patients. Clinical Advances in Hematology and Oncology. 12:15-17.
    555. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients with Chronic Myeloid Leukemia in the Community Setting. Clinical Lymphoma, Myeloma and Leukemia. 15:599-605.
    556. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase. The Lancet Haematology.
    557. Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies. ONCOLOGY (United States). 26.
    558. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia. The Lancet Haematology. 2:e118-e128.
    559. Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Opinion on Orphan Drugs. 1:607-623.
    560. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes. Biology of Blood and Marrow Transplantation.
    561. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion. Leukemia and Lymphoma. 56:711-715.
    562. ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia. American Journal of Hematology. 85:283-286.
    563. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Review of Hematology. 1-6.
    564. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:323-334.
    565. Management of imatinib-resistant patients with chronic myeloid leukemia. Therapeutic Advances in Hematology. 4:103-117.
    566. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 122:3336-3343.
    567. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica. 101:e324-e327.
    568. TP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.
    569. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.
    570. Frontline therapy. 107-128.
    571. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.
    572. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 16:139-145.
    573. American Journal of Hematology. 92:E3-E4.
    574. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    575. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME). The Lancet Oncology.
    576. Decitabine in myelodysplastic syndromes. Therapy. 2:835-842.
    577. Personalized medicine and targeted therapy of leukemia. 815-844.
    578. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. American Journal of Hematology. 90:E211-E212.
    579. Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia. American Journal of Clinical Oncology: Cancer Clinical Trials.
    580. Polycythemia vera. Journal of Clinical Oncology. 33:3953-3960.
    581. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 30:268-273.
    582. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. British Journal of Haematology.
    583. Phase i trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leukemia and Lymphoma. 56:395-400.
    584. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma, Myeloma and Leukemia. 16:616-624.
    585. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplantation. 52:28-33.
    586. Myeloid neoplasms after breast cancer. Leukemia and Lymphoma. 56:1012-1019.
    587. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39:1367-1374.
    588. Should treatment of philadelphia chromosome-positive acute lymphoblastic leukemia be intensive?. Clinical Advances in Hematology and Oncology. 14:892-896.
    589. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. American Journal of Hematology. 92:155-160.
    590. Nilotinib for the treatment of chronic myeloid leukemia after imatinib failure. American Journal of Hematology/ Oncology. 7.
    591. Standard Management of Patients with Chronic Myeloid Leukemia. 71-85.
    592. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    593. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. Journal of Infection and Chemotherapy. 21:663-667.
    594. Unraveling Myelodysplastic Syndromes. Current Oncology Reports. 18:1-11.
    595. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes. Cancer.
    596. Management of B-Cell Acute Lymphoblastic Leukemia. 22-28.
    597. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer.
    598. Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen [2]. Blood. 110:1698-1699.
    599. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer.
    600. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. The Lancet.
    601. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer.
    602. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    603. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Therapeutic Advances in Hematology. 6:253-261.
    604. The clinical challenge of imatinib resistance in chronic myeloid leukemia. Targeted Oncology. 1:186-196.
    605. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer.
    606. A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.
    607. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.
    608. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer.
    609. Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. Journal of Clinical Pathology.
    610. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Therapeutic Advances in Hematology. 5:29-34.
    611. Management of chronic myeloid leukemia (CML). 167-174.
    JABBOUR's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (749) concept(s)
    _
    Co-Authors Expand Description
    See all (127) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department